X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2138) 2138
Magazine Article (14) 14
Book Chapter (4) 4
Conference Proceeding (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Government Document (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1394) 1394
hydrazines - therapeutic use (1147) 1147
male (815) 815
female (696) 696
index medicus (693) 693
animals (683) 683
middle aged (469) 469
hydrazines - pharmacology (431) 431
adult (394) 394
aged (366) 366
pyrazoles - therapeutic use (326) 326
benzoates - therapeutic use (323) 323
mice (273) 273
pharmacology & pharmacy (265) 265
rats (258) 258
hydrazines (226) 226
hydrazines - administration & dosage (215) 215
parkinson disease - drug therapy (213) 213
antineoplastic agents - therapeutic use (212) 212
hydrazines - chemistry (206) 206
hydrazine (194) 194
oncology (194) 194
hydrazines - adverse effects (185) 185
hematology (181) 181
receptors, thrombopoietin - agonists (176) 176
dose-response relationship, drug (174) 174
purpura, thrombocytopenic, idiopathic - drug therapy (173) 173
eltrombopag (156) 156
clinical trials as topic (147) 147
levodopa - therapeutic use (146) 146
cancer (141) 141
receptors, fc - therapeutic use (130) 130
time factors (129) 129
thrombocytopenia (125) 125
drug therapy, combination (124) 124
treatment outcome (124) 124
thrombopoietin - therapeutic use (121) 121
benserazide - therapeutic use (118) 118
adolescent (114) 114
biochemistry & molecular biology (114) 114
chemistry, medicinal (114) 114
recombinant fusion proteins - therapeutic use (114) 114
analysis (111) 111
cell line, tumor (108) 108
carbidopa - therapeutic use (104) 104
platelet count (99) 99
thrombocytopenia - drug therapy (99) 99
drug synergism (98) 98
chemistry, multidisciplinary (95) 95
dihydroxyphenylalanine - therapeutic use (95) 95
benzoates - adverse effects (94) 94
pyrazoles - adverse effects (94) 94
hodgkin disease - drug therapy (89) 89
thrombopoietin (85) 85
hydrazines - chemical synthesis (83) 83
research (83) 83
apoptosis (82) 82
chemistry (81) 81
derivatives (81) 81
double-blind (81) 81
toxicology (80) 80
purpura (78) 78
benzoates - administration & dosage (76) 76
pyrazoles - administration & dosage (76) 76
child (73) 73
antineoplastic agents - pharmacology (72) 72
health aspects (72) 72
neoplasms - drug therapy (72) 72
romiplostim (69) 69
aged, 80 and over (68) 68
medicine, general & internal (68) 68
care and treatment (67) 67
cell biology (67) 67
structure-activity relationship (67) 67
drug combinations (65) 65
research article (65) 65
chronic disease (64) 64
drug therapy (64) 64
in-vitro (64) 64
proteins (64) 64
tuberculosis (64) 64
in vitro techniques (63) 63
management (63) 63
pyrazoles - pharmacology (63) 63
molecular structure (62) 62
drug evaluation (61) 61
vinblastine - therapeutic use (61) 61
splenectomy (60) 60
levodopa - administration & dosage (58) 58
rats, sprague-dawley (58) 58
administration, oral (57) 57
chemotherapy (57) 57
efficacy (57) 57
inhibition (57) 57
nicotinic acids - therapeutic use (57) 57
oxidative stress (57) 57
aromatic amino acid decarboxylase inhibitors (55) 55
picrates (55) 55
cell survival - drug effects (54) 54
cytotoxicity (54) 54
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1762) 1762
French (102) 102
German (84) 84
Russian (63) 63
Italian (52) 52
Japanese (36) 36
Spanish (36) 36
Polish (21) 21
Danish (8) 8
Chinese (7) 7
Portuguese (7) 7
Romanian (3) 3
Czech (2) 2
Norwegian (2) 2
Swedish (2) 2
Bulgarian (1) 1
Croatian (1) 1
Dutch (1) 1
Finnish (1) 1
Hebrew (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 06/2018, Volume 13, Issue 6, p. e0198184
... of splenectomy (Splx) as the first and still successfully used therapeutic measure in management of immune thrombocytopenia (ITP) [1]. The second therapeutic measure... 
AUTOIMMUNE THROMBOCYTOPENIA | TREATMENT OPTIONS | ADULT PATIENTS | INTRAVENOUS GAMMA-GLOBULIN | MANAGEMENT | ANTI-D | MEDICAL THERAPY | SAFETY | PURPURA | ROMIPLOSTIM | MULTIDISCIPLINARY SCIENCES | Prednisolone - adverse effects | Azathioprine - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunoglobulins, Intravenous - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Male | Dapsone - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Splenectomy | Young Adult | Aged, 80 and over | Child | Rituximab - adverse effects | Purpura, Thrombocytopenic, Idiopathic - surgery | Combined Modality Therapy | Remission Induction | Cyclosporine - therapeutic use | Dexamethasone - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Rho(D) Immune Globulin - adverse effects | Cyclosporine - adverse effects | Adolescent | Rho(D) Immune Globulin - therapeutic use | Dapsone - adverse effects | Benzoates - adverse effects | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - therapy | Rituximab - therapeutic use | Adult | Female | Prednisolone - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Drug Resistance | Pyrazoles - adverse effects | Hydrazines - therapeutic use | Treatment Outcome | Thrombopoietin - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Azathioprine - adverse effects | Hydrazines - adverse effects | Thrombocytopenic purpura | Clinical trials | Treatment outcome | Care and treatment | Analysis | Drugs | Thrombocytopenia | Therapy | Immunoglobulins | Dexamethasone | Intravenous administration | Medical treatment | Patients | Immunosuppressive agents | Bleeding | Medicine | Remission | Clinical medicine | Azathioprine | Drug dosages | Prednisolone
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1540 - 1550
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 2, pp. 442 - 452.e1
Journal Article
Drugs, ISSN 0012-6667, 2001, Volume 61, Issue 4, pp. 499 - 514
Journal Article
PLOS ONE, ISSN 1932-6203, 09/2019, Volume 14, Issue 9, p. e0222228
Ewing Sarcoma (ES) is characterized by recurrent translocations between EWSR1 and members of the ETS family of transcription factors. The transcriptional... 
TRIAL | GENOMIC LANDSCAPE | ANTAGONIST | MECHANISM | MULTIDISCIPLINARY SCIENCES | GROWTH | OSTEOSARCOMA | PANOBINOSTAT | CHEMOTHERAPY | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Irinotecan - administration & dosage | Histone Demethylases - antagonists & inhibitors | Humans | Histone Deacetylase Inhibitors - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Irinotecan - therapeutic use | Cyclophosphamide - therapeutic use | Vincristine - administration & dosage | Depsipeptides - therapeutic use | Bone Neoplasms - drug therapy | Hydrazines - administration & dosage | Doxorubicin - administration & dosage | Hydrazines - therapeutic use | Bone Neoplasms - enzymology | Etoposide - administration & dosage | Etoposide - therapeutic use | Histone Deacetylases - metabolism | Sarcoma, Ewing - drug therapy | Drug Synergism | Drug Therapy, Combination - methods | Sulfonamides - therapeutic use | Vincristine - therapeutic use | Cell Line, Tumor | Histone Deacetylases - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Sarcoma, Ewing - enzymology | Sulfonamides - administration & dosage | Depsipeptides - administration & dosage | Epigenetic inheritance | Chemotherapy | Usage | Care and treatment | Prognosis | Genetic aspects | Drug therapy, Combination | Research | Genetic transcription | Ewing's sarcoma | Risk factors | Cancer | Pediatrics | Biotechnology | Histone deacetylase | Transcription factors | Clinical trials | Cancer therapies | Doxorubicin | FLI-1 protein | Ewings sarcoma | Metabolites | Cell cycle | Histones | Experimentation | Teenagers | Translocation | Medical research | Young adults | Sarcoma | Etoposide | NuRD protein | Tumor cell lines | Vincristine | Irinotecan | Cyclophosphamide | Bone cancer | Inhibitors | Lysine | Reagents | Epigenetics | Prostate cancer
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2008, Volume 99, Issue 1, pp. 4 - 13
Summary Idiopathic thrombocytopenic purpura (ITP) is characterized by a low platelet count, which is the result of both increased platelet destruction and... 
Thrombocytopenia | Platelet immunology | immunity | Review Article | Immunity | FC-GAMMA RECEPTORS | thrombocytopenia | platelet immunology | COMMON VARIABLE IMMUNODEFICIENCY | CD40 LIGAND | IN-VITRO | ANTI-CD20 MONOCLONAL-ANTIBODY | INTRAVENOUS IMMUNOGLOBULIN-G | CIRCULATING THROMBOPOIETIN | AUTOREACTIVE T-CELLS | HEALTHY-INDIVIDUALS | PLATELET COUNT | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Glucocorticoids - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Blood Platelets - immunology | Autoantibodies - blood | Humans | Recombinant Fusion Proteins | Thrombopoietin | Purpura, Thrombocytopenic, Idiopathic - blood | Receptors, Fc - therapeutic use | Splenectomy | Purpura, Thrombocytopenic, Idiopathic - therapy | Purpura, Thrombocytopenic, Idiopathic - immunology | T-Lymphocytes - drug effects | Treatment Failure | Blood Platelets - drug effects | Carrier Proteins - therapeutic use | Thrombopoiesis - drug effects | Hematologic Agents - pharmacology | Immune Tolerance - drug effects | Purpura, Thrombocytopenic, Idiopathic - physiopathology | Hydrazines - therapeutic use | Hematologic Agents - therapeutic use | B-Lymphocytes - drug effects | Animals | Platelet Count | Immunoglobulins, Intravenous - therapeutic use | Cell Communication - drug effects | Immunologic Factors - pharmacology | Immunologic Factors - therapeutic use
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2016, Volume 2016, Issue 10, p. CD012055
Journal Article
Cancer, ISSN 0008-543X, 09/2019, Volume 125, Issue 18, pp. 3121 - 3130
Patients with acute myeloid leukemia (AML) who achieve a morphologic complete remission still can have measurable residual disease (MRD) detected by... 
acute myeloid leukemia (AML) | clinical trials | complete remission | measurable residual disease (MRD) | Triazines - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Decitabine | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Transplantation, Homologous | Pyrrolidines - therapeutic use | Neoplasm, Residual | Molecular Diagnostic Techniques | Flow Cytometry | Aminopyridines - therapeutic use | Azacitidine | Cytogenetic Analysis | Leukemia, Myeloid, Acute - therapy | Triazoles - therapeutic use | Hydrazines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Hematopoietic Stem Cell Transplantation | In Situ Hybridization, Fluorescence | Nivolumab - therapeutic use | Enzyme Inhibitors - therapeutic use | Remission Induction | Leukemia, Myeloid, Acute - diagnosis | Antineoplastic Agents, Immunological - therapeutic use | Lenalidomide - therapeutic use | Protein Kinase Inhibitors - therapeutic use | para-Aminobenzoates - therapeutic use | Aniline Compounds - therapeutic use | Immunologic Factors - therapeutic use | AML | PROGNOSTIC IMPACT | GEMTUZUMAB OZOGAMICIN | HEMATOPOIETIC-CELL TRANSPLANTATION | RISK STRATIFICATION | IMPROVE OUTCOMES | RELAPSE | ONCOLOGY | FLOW-CYTOMETRY | DIRECTED THERAPY | Flow cytometry | Myeloid leukemia | Leukemia | Medical treatment | Health risks | Clinical trials | Transplantation | Patients | Hemopoiesis | Risk assessment | Cytogenetics | Remission | Acute myeloid leukemia
Journal Article